"Idiopathic pneumonia syndrome"

Aryl hydrocarbon receptor-targeted therapy for CD4+ T cell-mediated idiopathic pneumonia syndrome in mice. We previously demonstrated that interferon γ (IFN-γ) derived from donor T cells co-opts the indoleamine 2,3-dioxygenase 1 (IDO1) → aryl hydrocarbon receptor (AHR) axis to suppress idiopathic pneumonia syndrome (IPS). Here we report that the dysregulated expression of AP-1 family genes in Ahr

[Lung transplantation in a child with idiopathic pneumonia syndrome after hematopoietic stem cell transplantation]. 1例10岁急性髓系白血病男性患儿化疗后行异体造血干细胞移植（HSCT）。HSCT后4个月因“干咳、气促3 d”收治于上海儿童医学中心重症监护病房，迅速进展为呼吸衰竭，胸部CT显示双肺广泛磨玻璃影，肺组织病理诊断为特发性肺炎综合征，给予无创通气支持、糖皮质激素等治疗无效；HSCT后7个月在外院成功实施双肺移植术，术后1个月恢复良好。.

Lung Transplant for Patient With Idiopathic Pneumonia Syndrome. Idiopathic pneumonia syndrome (IPS) is a serious complication after hematopoietic stem cell transplantation. Despite the high mortality rate with medical management, there have been no reported cases of lung transplants for patients with IPS. We report a case involving a 44-year-old woman who developed IPS 5 months after

Influence of total body irradiation dose rate on idiopathic pneumonia syndrome in acute leukemia patients undergoing allogeneic hematopoietic cell transplantation. To determine the relationship between dose rate and other factors in the development of idiopathic pneumonia syndrome (IPS) in patients with acute lymphoblastic leukemia or acute myeloid leukemia who are undergoing total body

Targeting the Canonical NF-κB Pathway with a High Potency IKK2 Inhibitor Improves Outcomes in a Mouse Model of Idiopathic Pneumonia Syndrome Idiopathic pneumonia syndrome (IPS) is a noninfectious inflammatory disorder of the lungs that occurs most often after fully myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). IPS can be severe and is associated with high 1-year

The association between platelet transfusion and idiopathic pneumonia syndrome is unaffected by platelet product type. Methods used to produce platelet (PLT) components, pooling of PLT-rich plasma (PRP-PLT) and apheresis (AP-PLT), may variably contribute to the pathogenesis and severity of idiopathic pneumonia syndrome (IPS). We performed a retrospective cohort study of 906 allogeneic

Idiopathic pneumonia syndrome after hematopoietic cell transplantation: Evidence of occult infectious etiologies. Newer diagnostic methods may link more idiopathic pneumonia syndrome (IPS) cases to an infectious agent. Bronchoalveolar lavage (BAL) samples from 69 hematopoietic cell transplant (HCT) recipients with IPS diagnosed between 1992 and 2006 were tested for 28 pathogens (3 bacteria and 25

Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case Report. Posttransplant high-dose cyclophosphamide (pT-HDCy) following T-cell-replete haploidentical bone marrow (BM) transplantation has been successfully utilized to control alloreactivity, mainly was achieved without classical GVHD, the patient suffered from idiopathic pneumonia syndrome followed by thrombotic microangiopathy. Although idiopathic pneumonia syndrome and thrombotic microangiopathy improved after treatment, the patient's lymphoma rapidly progressed nonetheless. This outcome may suggest that the alloreactivity against the classical GVHD targets is successfully eradicated by pT-HDCy

A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome Following Allogeneic Stem Cell Transplantation.A Blood and Marrow Transplant Clinical Tri Idiopathic pneumonia syndrome (IPS) is a diffuse, noninfectious lung injury that occurs acutely after allogeneic hematopoietic cell

The association between red blood cell and platelet transfusion and subsequently developing idiopathic pneumonia syndrome after hematopoietic stem cell transplantation. Blood transfusions are common during hematopoietic stem cell transplantation (HSCT) and may contribute to lung injury. This study examined the associations between red blood cell (RBC) and platelet (PLT) transfusions and idiopathic pneumonia syndrome (IPS) among 914 individuals who underwent myeloablative allogeneic HSCT between 1997 and 2001. Patients received allogeneic blood transfusions at their physicians' discretion. RBCs, PLTs, and a composite of "other" transfusions were quantified as the sum of units received each 7-day period from 6 days before transplant until IPS onset, death, or Posttransplant Day 120. RBC

TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Idiopathic pneumonia syndrome (IPS) is an acute, noninfectious lung disorder associated with high morbidity and mortality after hematopoietic cell transplantation. Previous studies have suggested

Drug Reactions Not known Cardiac failure, Cardiomyopathy, Pericardial effusion Vascular disorders Not known Haemorrhage, Deep venous thrombosis and Lung embolism Respiratory, thoracic and mediastinal disorders Uncommon Interstitial lung disease, Pulmonary fibrosis, Idiopathic pneumonia syndrome, Pulmonary haemorrhage, Respiratory failure, Acute respiratory distress syndrome, Pneumonitis Not known

Prevention of non-infectious pulmonary complications after intra-bone marrow stem cell transplantation in mice. Non-infectious pulmonary complications including idiopathic pneumonia syndrome (IPS) and bronchiolitis obliterans syndrome (BOS), which are clinical and diagnostic manifestations of lung chronic graft-versus-host disease (GVHD), cause significant mortality after allogeneic stem cell

the outcomes “overall survival”, “therapy-related mortality” and “GVHD”. In addition, the newly included Bensinger 2012 study was the only study to report data on serious adverse events within this research question. All serious adverse events such as fatal infection (26% versus 4%), multi-organ failure (11% versus 0%), idiopathic pneumonia syndrome (6% versus 0%) and fatal acute

thrombotic microangiopathy and idiopathic pneumonia syndrome/diffuse alveolar haemorrhage. The endothelium represents a rational target for preventing and treating HCT complications arising from EC dysfunction and damage. Additionally, markers of endothelial damage may be useful in improving diagnosis of HCT-related complications and monitoring treatment effect. Continued research to effectively manage EC

is a common complication in the immediate peritransplant period and has a high mortality rate, very late development of CMV pneumonitis has also been reported. [94] LONIPCs include various pathological entities that appear after approximately 100 days from HSCT. These include bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia, and idiopathic pneumonia syndrome or interstitial

transplant causes organ injury. First-onset viral infections with human herpesvirus 6 or Epstein-Barr virus within 100 days after transplant increase the risk of developing idiopathic pneumonia syndrome (adjusted hazard ratio [aHR], 5.52; 95% confidence interval [CI], 1.61-18.96;  = 0.007; and aHR, 9.21; 95% CI, 2.63-32.18;  = 0.001, respectively). First infection with human cytomegalovirus increases risk of bronchiolitis obliterans syndrome (aHR, 2.88; 95% CI, 1.50-5.55;  = 0.002) and grade II-IV acute graft-versus-host disease (aHR, 1.59; 95% CI, 1.06-2.39;  = 0.02). Murine roseolovirus, a homolog of human herpesvirus 6, can also be reactivated in the lung and other organs after bone marrow transplantation. Reactivation of murine roseolovirus induced an idiopathic pneumonia syndrome-like phenotype

a major barrier to the overall success of HSCT. Infectious complications include pneumonia due to bacteria, viruses, and fungi, and most commonly occur during neutropenia in the early post-transplant period. Non-infectious complications include idiopathic pneumonia syndrome, peri-engraftment respiratory distress syndrome, diffuse alveolar hemorrhage, pulmonary veno-occlusive disease, delayed pulmonary